Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
Más filtros

Bases de datos
Tipo del documento
Intervalo de año de publicación
1.
J Med Chem ; 60(1): 307-321, 2017 01 12.
Artículo en Inglés | MEDLINE | ID: mdl-27981835

RESUMEN

The noninvasive imaging of MMP activity in vivo could have a high impact in basic research as well as in clinical applications. This approach can be established using radiolabeled MMP inhibitors (MMPIs) as tracers for the detection of activated MMPs by means of PET. However, the complexity of diseases associated with dysregulated MMP expression necessitates the imaging of distinct MMPs or MMP subgroups to distinguish their individual role in specific diseases. To this end, selective and potent MMP-13 inhibitors based on a N,N'-bis(benzyl)pyrimidine-4,6-dicarboxamide core have been synthesized and successfully radiolabeled with carbon-11, fluorine-18, and gallium-68. Selected radiolabeled candidates were evaluated in vitro and in vivo regarding their pharmacokinetic properties and metabolic stability.


Asunto(s)
Metaloproteinasa 13 de la Matriz/efectos de los fármacos , Inhibidores de Proteasas/farmacología , Radiofármacos/química , Animales , Evaluación Preclínica de Medicamentos , Técnicas In Vitro , Masculino , Ratones , Ratones Endogámicos BALB C , Inhibidores de Proteasas/síntesis química , Relación Estructura-Actividad
2.
Arch Pharm Res ; 38(6): 1108-16, 2015 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-25712888

RESUMEN

Matrix metalloproteinase-13 (MMP-13) plays a critical role in degrading major collagens in human cartilage under some pathological conditions such as osteoarthritis. To establish the therapeutic potential against cartilage degradation, the effects of 12 naturally-occurring triterpenoids and steroids on MMP-13 induction were examined in the human chondrocyte cell line, SW1353. They included coreanoside F1, suavissimoside R1, spicatoside A, 25(S)-ruscogenin, methyl protogracillin, hederagenin, loniceroside A, loniceroside B, loniceroside C, smilaxin A, smilaxin C, and ursolic acid. Among these, only spicatoside A and 25(S)-ruscogenin were found to inhibit MMP-13 expression in IL-1ß-treated SW1353 cells at a pharmacologically-relevant concentration of 10 µM. These effects were also supported by the finding that spicatoside A (20 µM) reduced glycosaminoglycan release from IL-1α-treated rabbit joint cartilage culture to some degree. When the cellular mechanisms of action of spicatoside A in MMP-13 inhibition were investigated, the blocking point was not found among the MMP-13 signaling molecules examined such as mitogen-activated protein kinases, activator protein-1, and nuclear transcription factor-κB. Instead, spicatoside A was found to reduce MMP-13 mRNA stability. All of these findings suggest that spicatoside A and 25(S)-ruscogenin have a therapeutic potential for protecting against cartilage breakdown in arthritic disorders.


Asunto(s)
Cartílago Articular/enzimología , Condrocitos/enzimología , Interleucina-1beta/farmacología , Metaloproteinasa 13 de la Matriz/biosíntesis , Metaloproteinasa 13 de la Matriz/efectos de los fármacos , Inhibidores de Proteínas Quinasas/farmacología , Saponinas/farmacología , Animales , Enfermedades de los Cartílagos/tratamiento farmacológico , Cartílago Articular/citología , Cartílago Articular/efectos de los fármacos , Línea Celular , Condrocitos/efectos de los fármacos , Regulación hacia Abajo/efectos de los fármacos , Glicosaminoglicanos/metabolismo , Humanos , Masculino , FN-kappa B/metabolismo , Plantas Medicinales/química , ARN Mensajero/biosíntesis , ARN Mensajero/efectos de los fármacos , Conejos , Espirostanos/farmacología , Espirostanos/uso terapéutico , Esteroides/farmacología , Triterpenos/farmacología
3.
J Orthop Res ; 28(1): 110-5, 2010 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-19623662

RESUMEN

The aim of our study was to evaluate the in vitro effect of an HMG-CoA reductase inhibitor, atorvastatin, on the expression of significant anabolic and catabolic genes in human osteoarthritic chondrocytes and to explore the metabolic pathways involved in this process. Human articular osteoarthritic chondrocytes were cultured in the presence and absence of atorvastatin (10 and 50 micromol/L) for 24 h. Metalloproteinase 13 (MMP-13), collagen type II (COL2A1), and aggrecan (AGC) mRNA expression levels were evaluated by real-time PCR, and protein expression levels by Western blot analysis. IL-1beta levels in culture medium was analyzed with ELISA. The effect of the treatment with the mevalonate isoprenoid derivatives farnesol and geranylgeraniol, or the cholesterol precursor squalene, was evaluated in the atorvastatin osteoarthritic chondrocyte cultures. Incubation of osteoarthritic chondrocyte cultures with atorvastatin produced a significant dose-dependent reduction in IL-1beta production. Atorvastatin supplementation in cultures produced a decrease in MMP-13 mRNA and protein expression levels, which was reversed by the addition of farnesol. Regarding AGC and COL2A1 mRNA expression, a significant increase was observed only in chondrocytes cultures treated with 50 micromol/L atorvastatin. Our findings suggest that atorvastatin may have potential chondroprotective effects mostly by reducing cartilage degradation.


Asunto(s)
Células Cultivadas/efectos de los fármacos , Condrocitos/efectos de los fármacos , Ácidos Heptanoicos/administración & dosificación , Inhibidores de Hidroximetilglutaril-CoA Reductasas/administración & dosificación , Osteoartritis de la Rodilla/prevención & control , Pirroles/administración & dosificación , Anciano , Anciano de 80 o más Años , Agrecanos/efectos de los fármacos , Agrecanos/metabolismo , Atorvastatina , Cartílago Articular/citología , Cartílago Articular/efectos de los fármacos , Cartílago Articular/metabolismo , Células Cultivadas/metabolismo , Condrocitos/metabolismo , Colágeno Tipo II/efectos de los fármacos , Colágeno Tipo II/metabolismo , Relación Dosis-Respuesta a Droga , Femenino , Humanos , Interleucina-1beta/efectos de los fármacos , Interleucina-1beta/metabolismo , Articulación de la Rodilla/citología , Articulación de la Rodilla/efectos de los fármacos , Articulación de la Rodilla/metabolismo , Masculino , Metaloproteinasa 13 de la Matriz/efectos de los fármacos , Metaloproteinasa 13 de la Matriz/metabolismo , Persona de Mediana Edad
4.
Arthritis Res Ther ; 11(2): R41, 2009.
Artículo en Inglés | MEDLINE | ID: mdl-19291317

RESUMEN

INTRODUCTION: The aims of this study were, first, to investigate the in vivo effects of treatment with avocado/soybean unsaponifiables on the development of osteoarthritic structural changes in the anterior cruciate ligament dog model and, second, to explore their mode of action. METHODS: Osteoarthritis was induced by anterior cruciate ligament transection of the right knee in crossbred dogs. There were two treatment groups (n = 8 dogs/group), in which the animals received either placebo or avocado/soybean unsaponifiables (10 mg/kg per day), which were given orally for the entire duration of the study (8 weeks). We conducted macroscopic and histomorphological analyses of cartilage and subchondral bone of the femoral condyles and/or tibial plateaus. We also conducted immunohistochemical analyses in cartilage for the following antigens: inducible nitric oxide synthase, matrix metalloproteinase (MMP)-1, MMP-13, a disintegrin and metalloproteinase domain with thrombospondin motifs (ADAMTS)4 and ADAMTS5. RESULTS: The size of macroscopic lesions on the tibial plateaus was decreased (P = 0.04) in dogs treated with the avocado/soybean unsaponifiables. Histologically, in these animals the severity of cartilage lesions on both tibial plateaus and femoral condyles, and the cellular infiltration in synovium were significantly decreased (P = 0.0002 and P = 0.04, respectively). Treatment with avocado/soybean unsaponifiables also reduced loss of subchondral bone volume (P < 0.05) and calcified cartilage thickness (P = 0.01) compared with placebo. Immunohistochemical analysis of cartilage revealed that avocado/soybean unsaponifiables significantly reduced the level of inducible nitric oxide synthase (P < 0.05) and MMP-13 (P = 0.01) in cartilage. CONCLUSIONS: This study demonstrates that treatment with avocado/soybean unsaponifiables can reduce the development of early osteoarthritic cartilage and subchondral bone lesions in the anterior cruciate ligament dog model of osteoarthritis. This effect appears to be mediated through the inhibition of inducible nitric oxide synthase and MMP-13, which are key mediators of the structural changes that take place in osteoarthritis.


Asunto(s)
Glycine max/química , Metaloproteinasa 13 de la Matriz/efectos de los fármacos , Óxido Nítrico Sintasa/efectos de los fármacos , Osteoartritis/tratamiento farmacológico , Persea/química , Fitosteroles/uso terapéutico , Extractos Vegetales/uso terapéutico , Vitamina E/uso terapéutico , Animales , Artritis Experimental/tratamiento farmacológico , Artritis Experimental/patología , Huesos/efectos de los fármacos , Huesos/patología , Cartílago/efectos de los fármacos , Cartílago/patología , Perros , Combinación de Medicamentos , Inmunohistoquímica , Metaloproteinasa 13 de la Matriz/metabolismo , Óxido Nítrico Sintasa/metabolismo , Osteoartritis/patología
5.
J Periodontol ; 79(10): 1934-41, 2008 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-18834249

RESUMEN

BACKGROUND: Matrix metalloproteinases (MMPs) play important roles in tissue-destruction mechanisms-associated periodontitis. MMP-8 and -13 are the predominant collagenases that are important in the extracellular matrix degradation in periodontal tissues. MMP-14 is a membrane-type MMP, whereas laminin-5 indicates basal membrane modification and epithelial induction. The purpose of the present study was to evaluate the effects of celecoxib and omega-3 fatty acid administration on the gingival tissue expression of MMP-8, -13, and -14, tissue inhibitor of MMP (TIMP)-1, and laminin (Ln)-5gamma2-chain in rat experimental periodontitis induced by Escherichia coli endotoxin (lipopolysaccharide [LPS]). METHODS: Experimental periodontitis was induced in rats by repeated LPS injection. Fifty-one adult male Sprague-Dawley rats were divided into six study groups: saline control, LPS, LPS + celecoxib, LPS + therapeutic omega-3 (TO3), prophylactic omega-3 + LPS + omega-3 (P+TO3), and LPS + celecoxib + omega-3 fatty acid. Celecoxib and omega-3 fatty acid were given as a single agent or as combination therapy for 14 days. On day 15, all rats were sacrificed, and gingival tissues were analyzed immunohistochemically for the expression of MMP-8, -13, and -14, TIMP-1, and Ln-5gamma2-chain. Alveolar bone loss was evaluated morphometrically under a stereomicroscope. Data were tested statistically by Kruskal-Wallis and Mann-Whitney tests and Spearman correlation analysis. RESULTS: Alveolar bone loss was significantly higher in all study groups compared to the saline control group (all P <0.01). MMP-8 expression was significantly higher in the LPS group than in the saline group (P = 0.001). Very low expression of MMP-8 was found in the celecoxib, P+TO3, and combination groups. TO3 increased TIMP-1 expression significantly compared to the LPS group (P <0.05). Individual celecoxib and P+TO3 administration increased MMP-14 significantly compared to saline control and LPS groups (P <0.05). No significant differences were found among the study groups with regard to Ln-5gamma2-chain and MMP-13 expressions (P >0.05). CONCLUSIONS: Selective cyclooxygenase-2 inhibitor, prophylactic omega-3 fatty acid, and a combination of these two agents can inhibit gingival tissue MMP-8 expression. Moreover, the individual administration of therapeutic omega-3 may increase gingival TIMP-1 expression in contrast to no effect on MMP-8, -13, and -14 expressions in experimental periodontitis. These experimental findings in a rat model of LPS-induced periodontitis need to be verified by clinical human studies.


Asunto(s)
Inhibidores de la Ciclooxigenasa 2/uso terapéutico , Ácidos Grasos Omega-3/uso terapéutico , Laminina/efectos de los fármacos , Metaloproteinasas de la Matriz/efectos de los fármacos , Periodontitis/tratamiento farmacológico , Pirazoles/uso terapéutico , Sulfonamidas/uso terapéutico , Inhibidor Tisular de Metaloproteinasa-1/efectos de los fármacos , Pérdida de Hueso Alveolar/tratamiento farmacológico , Pérdida de Hueso Alveolar/enzimología , Pérdida de Hueso Alveolar/patología , Animales , Celecoxib , Modelos Animales de Enfermedad , Combinación de Medicamentos , Escherichia coli , Encía/efectos de los fármacos , Encía/enzimología , Gingivitis/tratamiento farmacológico , Gingivitis/enzimología , Gingivitis/patología , Laminina/análisis , Lipopolisacáridos , Masculino , Metaloproteinasa 13 de la Matriz/análisis , Metaloproteinasa 13 de la Matriz/efectos de los fármacos , Metaloproteinasa 14 de la Matriz/análisis , Metaloproteinasa 14 de la Matriz/efectos de los fármacos , Metaloproteinasa 8 de la Matriz/análisis , Metaloproteinasa 8 de la Matriz/efectos de los fármacos , Metaloproteinasas de la Matriz/análisis , Periodontitis/enzimología , Periodontitis/patología , Ratas , Ratas Sprague-Dawley , Inhibidor Tisular de Metaloproteinasa-1/análisis
6.
Malays J Pathol ; 30(2): 95-102, 2008 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-19291918

RESUMEN

The effect of water extracts of Euphorbia hirta on the histological features and expressions of matrix metalloproteinases (MMPs) and tissue inhibitors of matrix metalloproteinases (TIMPs) in the rat articular cartilage was investigated. Arthritis was induced in rats using Freund's Complete Adjuvant containing heat-killed M. tuberculosis, and treated with water extracts of E. hirta. Paraffin tissue sections of the arthritic joints were evaluated. The extent of cartilage degeneration was found to be greatest in rats treated with the highest dosage of E. hirta, followed by rats in the untreated group. Rats treated with the intermediary and low dosages of Euphorbia hirta showed improved histology. MMP-13 levels were found to be decreased with decreasing dosages of E. hirta. TIMP-1 levels were found to increase with decreasing dosages of E. hirta. MMP-3 levels fluctuated without any appreciable pattern. Low dosages of E. hirta seem to be beneficial in reducing cartilage degeneration in cases of arthritis.


Asunto(s)
Artritis Experimental/tratamiento farmacológico , Enfermedades de los Cartílagos/patología , Euphorbia , Fitoterapia , Extractos Vegetales/administración & dosificación , Animales , Artritis Experimental/complicaciones , Enfermedades de los Cartílagos/etiología , Relación Dosis-Respuesta a Droga , Inmunohistoquímica , Metaloproteinasa 13 de la Matriz/efectos de los fármacos , Metaloproteinasa 13 de la Matriz/metabolismo , Metaloproteinasa 3 de la Matriz/efectos de los fármacos , Metaloproteinasa 3 de la Matriz/metabolismo , Ratas , Ratas Wistar , Inhibidor Tisular de Metaloproteinasa-1/efectos de los fármacos , Inhibidor Tisular de Metaloproteinasa-1/metabolismo
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA